EUCTR2019-000415-87-DE进行中（未招募）1 期
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO) - Assessment of safety & antitumor activity of GSK3377794 in NY-ESO-1+ and/or LAGE-1a+ solid tumors
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 97
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. For participants <18 years of age, (or the legal minimum age in the relevant country) their legal guardian must give informed consent.Pediatric subjects will be included in age-appropriate discussion in order to obtain assent.
- •2.Participant must be =10 years of age at the time of signing the informed consent.(Germany-Participant must be >= 18 years of age at the time of signing the informed consent). Participant scheduled to receive clinical drug product supply must also weigh =40 kg. For participant scheduled to receive intended commercial drug product supply and weighing <40kg, the Investigator must also consult with the Medical Monitor prior to inclusion.
- •3.Participant has a diagnosis of synovial sarcoma or myxoid/ round cell liposarcoma, confirmed by local histopathology with evidence of disease specific translocation.
- •Note: Evidence of a relevant disease-specific translocation is required at latest prior to leukapheresis (Inclusion 8).
- •4. Participant has advanced (metastatic or unresectable) synovial sarcoma or myxoid/round cell liposarcoma. Unresectable refers to a tumor lesion in which clear surgical excision margins cannot be obtained without leading to significant functional compromise.
- •5. Male or female. Contraception requirements will apply at the time of leukapheresis and treatment.
- •6. A representative tumor tissue specimen (archived or fresh biopsy) with associated pathology report should be available to perform NY-ESO-1 antigen expression analysis, unless a recent NY-ESO-1 expression test result from the same designated central laboratory, following the same procedures, has already been performed under a separate GSK sponsored protocol or under another substudy. For guidance on acceptable specimen material see Tumor Biopsies under Section 5.1 Leukapheresis Eligibility Screening
- •-Prior to finalizing participant treatment plan, please note that bridging/standard of care anti-cancer therapy is allowed under Section 7.1.2 conditions but that there are washout requirements prior to leukapheresis and prior to lymphodepletion. Additional considerations should be given to accumulated radiotherapy prior to lymphodepletion. All the Inclusion Criteria from Section 6.1.1 must apply
- •again prior to leukapheresis. In addition, the following criteria must also apply:
- •7. Life expectancy =24 weeks
- •8. Participant has confirmed evidence of a relevant disease-specific translocation per below:
- •For synovial sarcoma, presence of a translocation involving chromosome 18 (SYT gene) and/or chromosome X (SSX1, SSX2 or SSX4 genes);
- •For myxoid/round cell liposarcoma, presence of a translocation involving chromosome 12 (DDIT3 gene) and/or chromosome 16 (FUS gene) and/or chromosome 22 (EWSR1 gene).
- •Note: Methods, such as, but not limited to, fluorescence in situ hybridization (FISH) assay or Next Generation Sequencing (NGS) or Immuno HistoChemistry (IHC) using fusion-specific antibody are commonly used to detect translocations.
- •9. Participant is either currently being treated with or has completed at least one standard-of-care treatment including anthracycline-containing regimens (e.g., doxorubicin alone, doxorubicin with ifosfamide) for advanced (metastatic or inoperable) disease. Participants who are intolerant to anthracycline may receive ifosfamide alone unless intolerant to or ineligible to receive ifosfamide. Participants who received anthracycline-based therapy in the neoadjuvant/adjuvant setting and progressed will be eligi
排除标准
- •1.Participant has been previously treated for advanced (metastatic or unresectable) synovial sarcoma or myxoid/round cell liposarcoma.
- •2. Central nervous system metastases.
- •3. Any other prior malignancy that is not in complete remission.
- •Exceptions include:
- •a. completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma (e.g. melanoma in situ, basal cell carcinoma, prostate cancer in-situ, periosteal osteosarcoma)
- •b. previous malignancies that have been definitively treated, and have been in remission for 5 years may be enrolled upon consultation with sponsor Medical Monitor or designee
- •4. Previous treatment with genetically engineered NY-ESO-1-specific T cells.
- •5. Previous NY-ESO-1 vaccine or NY-ESO-1 targeting antibody.
- •6. Prior gene therapy using an integrating vector.
- •7. Previous allogeneic hematopoietic stem cell transplant.
- •8. Clinically significant systemic illness: serious active infections or significant cardiac, pulmonary, hepatic or other organ dysfunction, that in the judgment of the Investigator would compromise the subject’s ability to tolerate protocol therapy or significantly increase the risk of complications, or, prior or active demyelinating disease.
- •Leukapheresis Eligibility Screening: Participants are not eligible for leukapharesis if any of the Exclusion criteria from section 6.2.1 apply. Please note in particular that mandatory washout period restrictions must be respected (Table 5) before starting leukapheresis. In addition, participants are not eligible for leukapharesis if any of the following criteria apply:
- •9.Participant has history of chronic or recurrent (within the last year prior to leukapheresis) severe autoimmune or immune mediated disease (e.g. Crohn’s disease, systemic lupus) requiring steroids or other immunosuppressive treatments.
- •10. Uncontrolled intercurrent illness including, but not limited to:
- •a. Ongoing or active infection (including, but not limited to systemic fungal infection)
- •b. Clinically significant cardiac disease defined by congestive heart failure New York Heart Association (NYHA) Class 3 /Class 4
- •c. Uncontrolled clinically significant arrhythmia
- •d. Acute coronary syndrome (angina or myocardial infarction) in last 6 months
- •e. Interstitial lung disease (participants with existing pneumonitis as a result of radiation are not excluded; however, participants cannot be oxygen dependent)
- •11. Current active liver or biliary disease.
- •12. QTc >480 msec
- •13. Participant has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide, fludarabine, other agents used in the study.
- •14. Pregnant or breastfeeding females (due to risk to fetus or newborn).
- •15. Prior/concomitant therapy: any prior treatment-related toxicities must be Common terminology criteria for adverse events <=Grade 1 at the time of initiating study intervention (except for non-clinically significant toxicities). Other standard of care lines of therapy are allowed only if guidelines and washout periods are followed.
- •16. Investigational treatment within 30 days or 5 half-lives (whichever is shorter) prior to leukapheresis. Investigational vaccines (other than NY-ESO-1 vaccines that are not allowed) must follow the washout period specified in Table 6. Exceptions to this rule must be evaluated by the Investigator in agreement with the Sponsor's Medical Monitor
- •17. Participant has active infection with HIV, HBV, H
研究者
相似试验
进行中（未招募）
1 期
A study of NY-ESO-1 T-cells (GSK3377794) in synovial sarcoma patientsMedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Synovial sarcomaEUCTR2019-000415-87-ITGLAXOSMITHKLINE RESEARCH AND DEVELOPMENT65
进行中（未招募）
1 期
A study of NY-ESO-1 T-cells (GSK3377794) in synovial sarcoma and myxoid/round cell liposarcoma patientsSynovial sarcoma and Myxoid/Round Cell Liposarcoma (MRCLS)MedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073137Term: Myxoid liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10073139Term: Round cell liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-000415-87-NLGlaxoSmithKline Research & Development Ltd97
进行中（未招募）
1 期
A study of NY-ESO-1 T-cells (GSK3377794) in synovial sarcoma and myxoid/round cell liposarcoma patientsSynovial sarcoma and Myxoid/Round Cell Liposarcoma (MRCLS)MedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073137Term: Myxoid liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-000415-87-GBGlaxoSmithKline Research & Development Ltd80
招募中
1 期
A study of NY-ESO-1 T-cells (GSK3377794) in synovial sarcoma and myxoid/round cell liposarcoma patientsSynovial sarcoma and Myxoid/Round Cell Liposarcoma (MRCLS)MedDRA version: 21.1Level: PTClassification code: 10073139Term: Round cell liposarcoma Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10073137Term: Myxoid liposarcoma Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10042863Term: Synovial sarcoma Class: 100000004864CTIS2024-513032-14-00Adaptimmune LLC87
进行中（未招募）
1 期
A study of NY-ESO-1 T-cells (GSK3377794) in synovial sarcoma patientsMedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Synovial sarcomaEUCTR2019-000415-87-FRGlaxoSmithKline Research & Development Ltd65